Scarica l'app Stockscreener
12.79
0.39%
-0.05
Dopo l'orario di chiusura:
12.80
0.01
+0.08%
Precedente Chiudi:
$12.84
Aprire:
$13.1
Volume 24 ore:
1.21M
Relative Volume:
0.99
Capitalizzazione di mercato:
$732.39M
Reddito:
-
Utile/perdita netta:
$-52.79M
Rapporto P/E:
-16.42
EPS:
-0.7789
Flusso di cassa netto:
$-53.49M
1 W Prestazione:
+4.66%
1M Prestazione:
-2.22%
6M Prestazione:
+149.80%
1 anno Prestazione:
+782.07%
Intervallo 1D:
$12.37
$14.41
Intervallo di 1 settimana:
$12.25
$14.41
Portata 52W:
$1.36
$14.41
Climb Bio Inc Stock (CLYM) Company Profile
Nome
Climb Bio Inc
Settore
Industria
Telefono
1-866-857-2596
Indirizzo
20 WILLIAM STREET, WELLESLEY HILLS
Compare CLYM vs VRTX, REGN, ARGX, RVMD, ALNY
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CLYM
Climb Bio Inc
|
12.79 | 735.26M | 0 | -52.79M | -53.49M | -0.7789 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Climb Bio Inc Stock (CLYM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-15 | Iniziato | Mizuho | Outperform |
| 2026-03-24 | Iniziato | B. Riley Securities | Buy |
| 2026-03-18 | Iniziato | Truist | Buy |
| 2026-03-11 | Iniziato | Raymond James | Strong Buy |
| 2026-03-05 | Iniziato | Wedbush | Outperform |
| 2026-02-13 | Iniziato | Piper Sandler | Overweight |
| 2025-10-16 | Iniziato | William Blair | Outperform |
| 2025-10-13 | Iniziato | H.C. Wainwright | Buy |
| 2025-08-15 | Iniziato | Robert W. Baird | Outperform |
| 2025-06-06 | Iniziato | Oppenheimer | Outperform |
| 2025-05-22 | Iniziato | BTIG Research | Buy |
| 2024-12-02 | Iniziato | Leerink Partners | Outperform |
Mostra tutto
Climb Bio Inc Borsa (CLYM) Ultime notizie
Climb Bio Inc (CLYM) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
CLYM Maintained by Wedbush -- Price Target Raised to $20.00 - GuruFocus
Wedbush Raises Price Target on Climb Bio to $20 From $17, Keeps Outperform Rating - Moomoo
Climb Bio Inc (CLYM) Cash Flow - TradingKey
Climb Bio Inc (CLYM) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Climb Bio Inc (CLYM) Institutional Confidence - TradingKey
Climb Bio Inc (CLYM) Valuation: PE, PB & Fair Value Analysis - TradingKey
CLYM|Climb Bio Inc|Price:12.840|Chg%:+0.080 - TradingKey
Climb Bio: Three Key Kidney Disease Readouts In Q4 Ought To Generate Volatility (CLYM) - Seeking Alpha
Frontier tech research, news & data - MLQ.ai
AI Investing InsightsOfficial HomepageIntellectia AI™ - Intellectia AI
FMR LLC's Strategic Acquisition of Climb Bio Inc Shares - GuruFocus
Q32 Bio Shares Climb Ahead of Drug Trial Results for Alopecia Treatment - Moomoo
Climb Bio Inc. (CLYM) Edges Lower Amid Mixed Biotech Sentiment, Key Support Levels in FocusWeak Sell Signals - DonanımHaber
Climb Bio Inc. (CLYM) Q1 2026 Earnings: Smaller-Than-Expected Loss Signals Cost DisciplineNegative Surprise Momentum - dars.gov.et
Climb Bio, Inc. advances CD19-based approach to preserve protective antibody function - Traders Union
Is Artiva Biotherapeutics, Inc. (ARTV) Outperforming Other Medical Stocks This Year? - Yahoo Finance
CLYM Q1 2026 Earnings: Narrower Loss than Expected, Stock Edges HigherPost-Announcement Reaction - DonanımHaber
Form 13D/A Climb Bio For: 7 July By Investing.com - Investing.com Nigeria
5 Biotech Stocks That Delivered 100% To 300% Gains: Did Your Winning Trades Offset Portfolio Losses? - RTTNews
Climb Bio Inc. (CLYM) Q1 2026 Earnings: EPS Beat Partially Offsets Market Skepticism as Pre-Revenue Biotech Navigates Clinical ProgressDividend Earnings Report - dars.gov.et
Climb Bio Appoints Breanna O’Reilly to Board - The Globe and Mail
Climb Bio, Inc. Files Form 8-K: Key Company Information, NASDAQ Listing, and Emerging Growth Status - Minichart
Form 4 Climb Bio Inc For: 1 July By Investing.com - Investing.com UK
70,284 Climb Bio (CLYM) share options granted for RA Capital-related funds - Stock Titan
Climb Bio (CLYM) director receives 70,284 stock options tied to RA Capital funds - Stock Titan
Climb Bio (CLYM) director Breanna Maurine Celebi files initial Form 3 - Stock Titan
Breanna O’Reilly joins Climb Bio (NASDAQ: CLYM) board with stock option grant - Stock Titan
Climb Bio, Inc. reveals on-target clinical results for budoprutug in new study - Traders Union
Climb Bio Insider Sold Shares Worth $406,979, According to a Recent SEC Filing - marketscreener.com
Form 4 Climb Bio Inc For: 30 June By Investing.com - Investing.com Canada
Form 144 CLIMB BIO For: 30 June By Investing.com - Investing.com Nigeria
Climb Bio CEO Aoife Brennan sells $406,979 in shares By Investing.com - Investing.com India
Climb Bio (CLYM) CEO sells 30,902 shares after RSU vesting - Stock Titan
[144] Climb Bio, Inc. SEC Filing - Stock Titan
Climb Bio, Inc.(NasdaqGM: CLYM) added to Russell 2000 Index - marketscreener.com
Climb Bio, Inc.(NasdaqGM: CLYM) added to Russell 2500 Growth Benchmark - marketscreener.com
Climb Bio, Inc.(NasdaqGM: CLYM) added to Russell 2000 Value Benchmark - marketscreener.com
Climb Bio, Inc. advances rare kidney disease collaboration with patient-centered approach - Traders Union
Climb Bio, Inc.(NasdaqGM: CLYM) added to Russell Microcap Growth Benchmark Index - marketscreener.com
Climb Bio, Inc.(NasdaqGM: CLYM) added to Russell 2000 Growth Benchmark - marketscreener.com
Climb Bio, Inc.(NasdaqGM: CLYM) added to Russell 3000E Growth Benchmark - marketscreener.com
CLYM Q1 2026 Earnings: Narrowed Loss Beat Expectations as Biotech Continues Pipeline DevelopmentProfit Margin Analysis - dars.gov.et
Climb Bio, Inc.(NasdaqGM: CLYM) added to Russell 3000 Index - marketscreener.com
Climb Bio, Inc.(NasdaqGM: CLYM) added to Russell 2000 Dynamic Index - marketscreener.com
CLYM Q1 2026 Earnings: Narrower-Than-Expected Loss Signals Cost DisciplineEarnings Expansion Phase - dars.gov.et
Climb Bio Q1 2026 Earnings: Bottom-Line Beat Provides Positive MomentumEPS Surprise History - dars.gov.et
Why is Climb Bio stock gaining Friday? - MSN
Price to sales forward of Climb Bio, Inc. – NASDAQ:CLYM - TradingView
Price to earnings forward of Climb Bio, Inc. – NASDAQ:CLYM - TradingView
Price to book forward of Climb Bio, Inc. – NASDAQ:CLYM - TradingView
Climb Bio Inc Azioni (CLYM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.97%
0.83%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):